Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06010875 | A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors | PHASE1 | RECRUITING | 48 | — | — | Nov 30, 2023 | Sep 30, 2026 | Nov 8, 2023 | 1 | China |
Therapy-related adverse events were recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0)
Dose-limiting toxicity after cell infusion
| Arm | Type | Description |
|---|---|---|
| Intravenous of CD70-targeted CAR-T | EXPERIMENTAL | Infusion of CD70-targeted CAR-T cells by dose of 1-10x10\^6 cells/kg |
| intraperitoneal injection of CD70-targeted CAR-T | EXPERIMENTAL | Infusion of CD70-targeted CAR-T cells by dose of 1-10x10\^6 cells/kg |
| Name | Type | Description |
|---|---|---|
| CD70 CAR-T cells | BIOLOGICAL | After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were transfused intravenically |
Inclusion Criteria: 1. Age ≥18 years old, male or female; 2. Advanced/metastatic solid tumor confirmed by histopathology or cytology (paraffin section or fresh biopsy tumor tissue specimen) (positive tumor CD70 expression (tumor CD70 positive (IHC 3+) confirmed by histology or pathology)) ; 3. At l...